Literature DB >> 2680154

[Observation on the efficacy of combined use of some new antimalarials for the treatment of falciparum malaria in Hainan Province].

L Chen, Z R Dai, Y L Qian, Z M Ma, F C Guo, Z H Liao, D D Fu, D Q Ma, X J Pang.   

Abstract

Field trials were carried out to assess the therapeutic effects including the combined use of piperaquine (PQ) with nitroquine (NQ) and pyronaridine (PYR) with NQ against falciparum malaria in regions of Hainan Province with chloroquine-resistance in 3 successive autumns from 1985 to 1987. In an evaluation of PQ 750 mg with NQ 25 mg therapy in 33 falciparum malaria patients, the average fever subsidence time and parasite clearance time were 39 hours and 49 hours respectively, but within 28 days after medication, the recrudescence rates were 0-47% in different regions. In evaluations of PYR 600 mg with NQ 25 mg in 11 cases, PYR 800 mg with NQ 40 mg in 43 cases, PYR 800 mg with NQ 80 mg in 31 cases, the fever subsidence time were 31-35 hours, the parasite clearance time were 46-53 hours and the 28 days recrudescence rates were 13-18%. In the control, the use of PYR 1,200 mg alone in 42 cases, the average fever subsidence time and parasite clearance time were 33 hours and 48 hours respectively, the 28 days recrudescence rate was 12%. There was no statistically significant difference among them in their effects. The side-effects of all groups were mild.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2680154

Source DB:  PubMed          Journal:  Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi        ISSN: 1000-7423


  5 in total

Review 1.  Piperaquine: a resurgent antimalarial drug.

Authors:  Timothy M E Davis; Te-Yu Hung; Ing-Kye Sim; Harin A Karunajeewa; Kenneth F Ilett
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Effects of a high-fat meal on the relative oral bioavailability of piperaquine.

Authors:  Ing-Kye Sim; Timothy M E Davis; Kenneth F Ilett
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

3.  Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria.

Authors:  Te-Yu Hung; Timothy M E Davis; Kenneth F Ilett; Harin Karunajeewa; Sean Hewitt; Mey Bouth Denis; Chiv Lim; Doung Socheat
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

Review 4.  Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria.

Authors:  Hasifa Bukirwa; B Unnikrishnan; Christine V Kramer; David Sinclair; Suma Nair; Prathap Tharyan
Journal:  Cochrane Database Syst Rev       Date:  2014-03-04

5.  Review of pyronaridine anti-malarial properties and product characteristics.

Authors:  Simon L Croft; Stephan Duparc; Sarah J Arbe-Barnes; J Carl Craft; Chang-Sik Shin; Lawrence Fleckenstein; Isabelle Borghini-Fuhrer; Han-Jong Rim
Journal:  Malar J       Date:  2012-08-09       Impact factor: 2.979

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.